World Investment Advisors Raises Stock Position in Pfizer Inc. $PFE

World Investment Advisors raised its stake in shares of Pfizer Inc. (NYSE:PFE) by 11.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 397,952 shares of the biopharmaceutical company’s stock after purchasing an additional 40,239 shares during the quarter. World Investment Advisors’ holdings in Pfizer were worth $9,909,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the stock. Triad Wealth Partners LLC increased its position in Pfizer by 1.9% during the 4th quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock valued at $510,000 after purchasing an additional 386 shares during the period. ETF Store Inc. increased its position in Pfizer by 3.8% during the 4th quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock valued at $272,000 after purchasing an additional 396 shares during the period. Mattern Wealth Management LLC increased its position in Pfizer by 4.6% during the 4th quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company’s stock valued at $228,000 after purchasing an additional 400 shares during the period. Pines Wealth Management LLC increased its position in Pfizer by 4.4% during the 4th quarter. Pines Wealth Management LLC now owns 9,430 shares of the biopharmaceutical company’s stock valued at $235,000 after purchasing an additional 400 shares during the period. Finally, Quest Investment Management LLC increased its position in Pfizer by 1.3% during the 3rd quarter. Quest Investment Management LLC now owns 31,768 shares of the biopharmaceutical company’s stock valued at $809,000 after purchasing an additional 405 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The European Commission approved an expanded indication for HYMPAVZI, giving Pfizer a new growth opportunity in hemophilia treatment and strengthening the company’s pipeline outlook. European Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors
• Positive Sentiment: Pfizer’s transaction with Rigel Pharmaceuticals for VEPPANU provides upfront and potential milestone payments while allowing Pfizer to retain an economic interest, which helps monetize the asset without carrying full commercialization risk. Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)
• Positive Sentiment: Analyst commentary suggests Pfizer could achieve high-single-digit revenue growth from 2029 as new launches, acquisitions, and pipeline expansion offset patent-loss pressure. Can Pfizer Achieve High Single-Digit Revenue CAGR From 2029?

Analysts Set New Price Targets

A number of brokerages have issued reports on PFE. Guggenheim boosted their price objective on shares of Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a research report on Tuesday, March 24th. Morgan Stanley boosted their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a research report on Friday, April 10th. Wall Street Zen raised shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. HSBC upped their target price on shares of Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, March 17th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a research report on Wednesday, February 4th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have issued a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $28.74.

Pfizer Stock Up 0.3%

NYSE:PFE opened at $25.96 on Thursday. The firm’s 50-day moving average price is $27.03 and its 200-day moving average price is $26.19. The company has a market capitalization of $147.93 billion, a PE ratio of 19.81 and a beta of 0.35. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. Pfizer Inc. has a 1-year low of $21.97 and a 1-year high of $28.75.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. The firm had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The company’s revenue was up 5.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.6%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer’s dividend payout ratio is 131.30%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.